初始阴性PSMA PET/CT后二次扫描的价值:前瞻性多中心PSMA PET注册研究结果
该研究基于加拿大安大略省复发性前列腺癌PSMA PET注册队列,纳入210例初始PSMA PET/CT阴性且后续接受第二次扫描的患者。第二次扫描阳性率为56.2%,低于基线扫描的68.4%(P=0.0002);血清PSA升高(PSA 0.5 ng/mL时阳性率66.9%)和PSA倍增时间小于12个月(阳性率64.7%)的患者检出率更高。第二次扫描后管理变更仍高达46.4%,结论认为初始阴性后二次PSMA PET/CT对近半数患者有临床影响。
要点
- 初始阴性后二次PSMA PET/CT阳性率56.2%,仍可检出疾病。
- PSA>0.5 ng/mL或PSA倍增时间<12个月时二次扫描阳性率更高。
- 二次扫描后46.4%患者管理变更,其中因盆腔外转移改挽救治疗更常见(11% vs 7.3%,P=0.0492)。
核心结论
- 初始PSMA PET/CT阴性后,超过半数生化失败患者第二次扫描可发现病灶。
- 第二次扫描对近50%患者的管理决策仍有高影响。
- PSA>0.5 ng/mL或PSA倍增时间<12个月的患者二次扫描更可能提供有效信息。
研究设计与样本
- 前瞻性多中心注册研究,纳入加拿大安大略省复发性前列腺癌PSMA PET注册中2018年10月至2022年9月招募的6个预设临床队列患者。
- 分析对象为接受超过1次PSMA PET/CT且初始扫描阴性的210例患者(注册总4140例)。
- 比较第二次扫描阳性率、血清PSA、PSA倍增时间及管理变更与基线数据。
主要发现
- 第二次PET扫描阳性率56.2%(118/210),低于基线PET扫描的68.4%(2832/4140),P=0.0002。
- 血清PSA为0.5 ng/mL时第二次扫描检出率66.9%(107/160),PSA倍增时间<12个月时检出率64.7%(75/116)。
- 疾病分布(局部区域 vs 远处)差异无显著性,但第二次PET扫描内脏转移更常见(8.5% [10/118] vs 2.2% [62/2832],P=0.00002)。
- 第二次PET扫描后管理变更频率46.4%(83/179),因盆腔外转移改挽救治疗更常见(11% [23/210] vs 7.3% [302/4140],P=0.0492)。
关键数值与推荐
- 第二次PSMA PET/CT阳性率56.2%(118/210),基线扫描阳性率68.4%(2832/4140),P=0.0002。
- PSA为0.5 ng/mL时第二次扫描检出率66.9%(107/160)。
- PSA倍增时间<12个月时第二次扫描检出率64.7%(75/116)。
- 第二次扫描内脏转移发生率8.5%(10/118),基线扫描2.2%(62/2832),P=0.00002。
- 第二次扫描后管理变更率46.4%(83/179),因盆腔外转移改挽救治疗11%(23/210)vs 7.3%(302/4140),P=0.0492。
临床怎么用
- 对初始PSMA PET/CT阴性的生化失败前列腺癌患者,可考虑再次行PSMA PET/CT以指导管理。
- PSA>0.5 ng/mL或PSA倍增时间<12个月的患者二次扫描更可能获益。
- 二次扫描发现内脏转移或盆腔外转移时,可能需调整挽救治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a paucity of data on the utility of a second prostate-specific membrane antigen (PSMA) PET/CT scan after an initial negative scan in patients with recurrent prostate cancer. The purpose of this study was to assess the utility of a second PSMA PET/CT scan in these patients. Methods: This cohort comprised patients in the PSMA PET Registry for Recurrent Prostate Cancer in Ontario, Canada, who were recruited in 1 of 6 predefined clinical cohorts between October 2018 and September 2022 who had more than 1 PSMA PET/CT scan and whose initial scan was negative. The scan positivity rate, serum prostate-specific antigen (PSA), PSA doubling time, and management change were compared with baseline data. Results: In total, 210 of the 4140 patients in the registry fulfilled the inclusion criteria for the current analysis. The positivity rate of the second PET scan was lower than the baseline PET scan (56.2% [118/210] vs. 68.4% [2832/4140], P = 0.0002). Detection rates were higher in patients with elevated serum PSA (66.9% [107/160] for PSA of 0.5 ng/mL) and a PSA doubling time of less than 12 mo (64.7% [75/116]). Although differences in disease distribution (locoregional vs. distant) were not significant, visceral metastases were more common on the second PET scan (8.5% [10/118] vs. 2.2% [62/2832], P = 0.00002). Management change after a second PET scan was less frequent but remained high (46.4% [83/179]), with more frequent change to salvage therapy for extrapelvic metastases (11% [23/210] vs. 7.3% [302/4140], P = 0.0492). Conclusion: More than half of patients with biochemical failure after primary therapy for prostate cancer who have an initial negative PSMA PET/CT scan may have disease identified on a second PSMA PET/CT scan. The impact of a second PSMA PET/CT scan remains high, with management change necessary for nearly 50% of patients. A second PSMA PET/CT scan after an initially negative scan is more likely to be informative among patients with a PSA greater than 0.5 ng/mL or a PSA doubling time of less than 12 mo.
引用
- Metser U, Bauman G, Rashid M, et al. Utility of PSMA PET/CT After an Initial Negative Scan: Results from a Prospective Multicenter PSMA PET Registry. J Nucl Med. 2026. PMID: 41991335. doi:10.2967/jnumed.126.272204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。